The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
987
November 8, 1996
View Complete Issue         Table of Contents 2019 
Gemcitabine for Treatment of Pancreatic Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Gemcitabine for Treatment of Pancreatic Cancer
November 8, 1996 (Issue: 987)
Gemcitabine (jem site a been) hydrochloride (Gemzar - Lilly), a nucleoside analog, has been approved by the US Food and Drug Administration for intravenous (IV) use in the first-line treatment of locally advanced or metastatic adenocarcinoma of the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Gemcitabine for Treatment of Pancreatic Cancer
Article code: 987c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.